Jonathan Liss, MD
Neurology · Columbus, GANPI 1386613743
Payments from drug & device makers
Across 1,803 payments — averaging $13,872 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$11.4M
- Eli Lilly$6M
- AbbVie$2.2M
- Genentech, Inc.$1.7M
- Roche Diagnostics Operations, Inc.$1.5M
- Biogen$1.4M
- plus $859K from 15 others
Across 6 payments — averaging $7740.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$46K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 1,192 | $11,430,499 |
| Eli Lilly | 58 | $5,960,352 |
| AbbVie(2 entities) | 277 | $2,169,008 |
| Genentech, Inc. | 74 | $1,748,647 |
| Roche Diagnostics Operations, Inc. | 14 | $1,473,216 |
| Biogen | 33 | $1,370,416 |
| Novartis | 7 | $579,994 |
| E.r. Squibb & Sons, L.L.C. | 16 | $147,877 |
| Avanir Pharmaceuticals, Inc. | 8 | $47,195 |
| Pfizer | 50 | $27,147 |
| Genentech USA, Inc. | 18 | $14,868 |
| Janssen Research & Development, LLC | 2 | $12,641 |
| Acadia Pharmaceuticals Inc | 5 | $7,128 |
| Corium, LLC | 16 | $7,110 |
| Merck | 11 | $4,940 |
| F. Hoffmann-la Roche AG | 2 | $4,880 |
| Roche Products Limited | 4 | $4,440 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $179 |
| Lilly USA, LLC | 1 | $107 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Baxter Healthcare | 1 | $15 |
How this compares
$25,010,702 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Columbus
- Reinaldo VersonColumbus$325K
- Marshall NashDecatur$13.6M
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Sandeep VaidLawrenceville$4.2M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- David LeschSuwanee$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.